In response to PMA treatment K562 myelogenous leukemia cells undergo megakaryocytic differentiation, which is dependent on prolonged ERK activation and is characterized by growth arrest, upregulation of CD41 and IL-6, and, finally, by characteristic changes in cell morphology. 
Introduction
The extracellular signal regulated kinases ERK1 and ERK2 (ERK1/2) are stimulated by growth and differentiation factors which signal through receptor tyrosine kinases, G proteincoupled receptors, and cytokine receptors.
1,2 ERK1 and ERK2 are 44-and 42-kDa enzymes, respectively, which become activated by dual phosphorylation of adjacent threonine and tyrosine residues in the activation lip (T183-G-Y185 in ERK2). ERK1/2 activation is mediated by the upstream dual specificity kinases MKK1 and MKK2, which themselves are activated by the Ras-regulated kinase Raf.
Once activated, ERK1/2 phosphorylate a broad spectrum of cytosolic and nuclear protein substrates to modulate their activity and/or interaction with other proteins. 2, 3 Among these substrates are components of signaling pathways and cytoskeletal proteins. In resting cells, ERK1/2 are predominantly cytosolic. Upon treatment of cells with growth factors or serum a fraction of ERK1/2 translocates to the nucleus, which is required for the phosphorylation of transcription factors and the modulation of gene expression. 4, 5 Dependent on the cell type and the stimulus used, ERK activation can lead to either cell proliferation or differentiation. In various cell systems, it has been shown that differentiation and proliferation in response to specific factors are associated with distinct kinetics of ERK activation (reviewed in Ref. 2) . For example, in the rat pheochromocytoma cell line PC12, treatment with epidermal growth factor (EGF) results in a short peak of ERK activity and cell proliferation while treatment of PC12 cells with nerve growth factor (NGF) results in prolonged ERK activation (several hours) and neurite outgrowth. Similarly, it was recently demonstrated that long-term ERK activity is necessary and sufficient for megakaryocytic differentiation of the pluripotent K562 cell line. 6, 7 In these cells a low constitutive level of ERK activity is required for proliferation and treatment of the cells with the MEK inhibitor PD098059 results in downregulation of ERK activity and upregulation of erythroid markers. 8, 9 Treatment of K562 cells with PMA, an activator of PKC, or expression of an activated MEK kinase induces prolonged ERK activity and megakaryocytic differentiation. 6, 7 This differentiation process is characterized by cell cycle arrest, a change in the adhesive properties of the cells, and changes in cell morphology.
The duration and magnitude of ERK activation is the result of the combined action of the upstream kinases and of protein phosphatases which inactivate ERK1/2 by dephosphorylating the regulatory sites in the activation lip. 2, 10 Since phosphorylation of both regulatory residues is required for ERK activity, dephosphorylation of either the phospho-threonine or the phospho-tyrosine residue is sufficient for ERK1/2 inactivation. Members of the serine/threonine protein phosphatases (PP1 and PP2A) as well as members of the family of dual specificity protein phosphatases, the MAP-kinase phosphatases (MKPs), have been identified as negative regulators of ERK1/2. In contrast to PP1 and PP2A, MKPs dephosphorylate both sites in the ERK activation lip. MKPs can be subdivided into two main groups: nuclear enzymes that can be induced in response to growth factors and stress (such as MKP-1, MKP-2 and PAC-1), and cytosolic enzymes which are not the products of immediate-early genes (such as MKP-3 and VH5). 10 Some of the immediate-early gene products have been suggested to be part of a negative feedback mechanism to downregulate ERK activity. More recently, the tyrosine-specific protein phosphatase (PTP) HePTP (also known as LC-PTP) was identified as an ERK1/2 phosphatase. [11] [12] [13] For example, overexpression of HePTP in Jurkat T cells blocks ERK1/2 activation after engagement of the T cell receptor and overexpression in K562 cells interferes with the activation of ERK1/2 in response to PMA. 11, 13, 14 In T cells, HePTP also binds and dephosphorylates the MAP-kinase family member p38 while in K562 cells ERK2 is the predominant substrate. HePTP is closely related to the PTPs, STEP and PTP-SL, which target ERK1/2 and p38 when overexpressed in fibroblasts. 15 STEP and PTP-SL are brain-specific enzymes while HePTP is predominantly expressed in hematopoietic cells. [16] [17] [18] [19] All three enzymes are localized in the cytosol and contain a highly conserved 15 amino acid sequence motif, the kinase interaction motif (KIM) within their N-termini. The KIM sequence is required for association with and dephosphorylation of active ERK1/2. [11] [12] [13] 15, 20 Within this sequence is a consensus site for phosphorylation by cAMP-dependent protein kinase (PKA). It was recently demonstrated that phosphorylation of this site in PTP-SL and HePTP in response to PKA activation inhibits the interaction of these phosphatases with their substrates and, consequently, results in increased ERK activity. 21, 22 In addition, HePTP can be phosphorylated within the N-terminus by activated ERKs and it was suggested that phosphorylation of these sites also interferes with the binding of HePTP to its substrates. 11 Therefore it was proposed that HePTP is involved in suppression of basal ERK activity in the absence of ERK activating signals.
While the regulation of ERKs by classic and tyrosine-specific MKPs has been extensively studied on a biochemical level, relatively little is known about their physiological function and how they affect the outcome of ERK activation. In the present report, we have studied the effect of HePTP on megakaryocytic differentiation of K562 cells which constitutively express this phosphatase 13 . As outlined above, proliferation and differentiation of K562 cells is largely determined by the magnitude and duration of ERK activity. We have used an antisense strategy to interfere with the function of HePTP and to study its role in the regulation of ERK activity and cell differentiation. The results show that HePTP is involved in regulating nuclear translocation of ERK2, rather than controlling its basal activity. Furthermore, the data indicate that the different steps during differentiation may differ with regard to their requirement for ERK activity and that HePTP can modulate megakaryocytic differentiation of K562 cells. The effect of HePTP downregulation in K562 cells on the expression of megakaryocytic markers and cell differentiation, for the first time, demonstrates that inhibition of this phosphatase has phenotypic consequences in a model system of hematopoietic cell differentiation.
Materials and methods

Expression constructs
Construction of the HePTP antisense expression vector: the HePTP cDNA was isolated from pCDNA3.1(−)myc-HisAHePTP 13 as a BamHI/XbaI fragment and ligated into pCDNA3.1HisA to reverse the orientation of the gene. The expression plasmid for ERK2 was a generous gift from Chandra Kumar (Schering Plough Research Institute).
Cells and transfections
K562 human chronic myelogenous leukemia cells were cultured in RPMI 1640 medium with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 U/ml streptomycin. Transfectants were obtained as described previously. 13 Polyclonal stable lines were established by placing cells under G418 (800 mg/ml) selection 48 h after transfection with continued growth under selection for 5 weeks prior to analysis. Clonal lines were established by serial dilution in 96-well plates. For stimulation with phorbol-12-myristate-13-acetate (PMA; Calbiochem, La Jolla, CA, USA) cells were starved overnight in FBS-free medium. For transient transfections 293 cells were seeded into six-well plates. The next day cells were transfected with 2 g of plasmid DNA per well using Fugene6 transfection reagent (Roche, Indianapolis, IN, Leukemia USA), according to the manufacturer's instructions. One day after transfection the cells were starved overnight in serumfree DMEM medium. The cells were stimulated with EGF (Roche) at a final concentration of 50 ng/ml.
Cell lysis and immunoblot
Cells were pelleted, lysed in 1 ml cold lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, pH 8.0, 1 g/ml aprotinin, 1 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium ortho-vanadate, and 10 mM NaF) and incubated for 20 min on ice. Lysates were then clarified by centrifugation at 19 000 r.p.m. for 20 min at 4°C.
Total cell lysates were resolved on 10% SDS-PAGE gels and transferred to nitrocellulose. Blots were incubated for 1 h in TBST (50 mM Tris, pH 7.5, 200 mM NaCl, 3 mM KCl, 0.05% Tween 20) containing 5% nonfat milk and incubated overnight with primary antibody in TBST/5% nonfat milk. Blots were washed with TBST and incubated for 1 h with secondary horseradish peroxidase (HRP)-conjugated antibody (BioRad, Hercules, CA, USA) in TBST/5% nonfat milk. After washing with TBST blots were developed using the Enhanced Chemiluminescence Detection System (Amersham, Piscataway, NJ, USA). Antibodies used for immunoblotting were anti-ERK2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-pERK which specifically detects tyrosine phosphorylated ERK1 and ERK2 (Santa Cruz Biotechnology), antipaxillin mAb (Transduction Labs, Lexington, KY, USA), anti-CDK6 mAb (Santa Cruz Biotechnology), anti-cyclin D polyclonal antiserum (a generous gift from Emma Lees, DNAX Research Institute), anti-T cellPTP mAb (Calbiochem), anti-PTP1B mAb (Transduction Labs), and anti-HePTP polyclonal antibody (Pettiford and Herbst). Protein concentrations were determined using BCA* Protein Assay Reagent (Pierce).
IL6 ELISA
Cells were starved overnight in serum-free medium. The following day cells were pelleted and resuspended in serum-free medium for an additional 2 h to keep basal ERK activity as low as possible. Cells were resuspended at 1 × 10 4 cells/200 l and for each cell line 200 l of cell suspension was plated in triplicate in 96-well plates. The cells were then treated with 100 nM PMA (Calbiochem) for 48 h or left untreated as a control. The cells were then pelleted by centrifugation and the supernatant was collected and stored at −20°C until further analysis. The IL6 content of the media was determined by ELISA (R&D Systems) according to the manufacturer's instruction.
Analysis of CD41 expression
Cells were serum starved as above (IL6 determination) and then left untreated or stimulated with PMA for 48 h. Cell cycle analysis 10 7 cells (1 × 10 6 cells/ml) per sample were serum starved as above and then left untreated or serum treated with 100 nM PMA for 24 h. Cells were collected by centrifugation and resuspended in 500 l PBS. While mixing 10 ml of 85% ethanol was added to each sample. After a 15 min incubation the cells were washed once in PBS containing 1% FBS and then resuspended in propidium iodide/RNAseA solution. The propidium iodide/RNAseA stock solution was prepared fresh by mixing PBS containing 1% FBS with 1/50 volume of propidium iodide stock solution (0.5 mg/ ml propidium iodide in sodium citrate, pH 7.0) and 1/40 volume of RNAseA stock solution (10 mg/ml RNAseA in 10 mM Tris-HCl, pH 7.5, 15 mM NaCl, boiled for 15 min and stored frozen at −20°C). The DNA content of the cells was then analyzed on a FACSCalibur (Becton Dickinson).
Cell fractionation
K562 cells were harvested by centrifugation, washed once with PBS and resuspended in buffer A (10 mM Hepes, pH 7.6, 15 mM KCl, 2 mM MgCl 2 , 0.1 mM EDTA, 1 mM sodium orthovanadate, 10 mM NaF, 0.5 mM PMSF, 10 g/ml leupeptin, 5 g/ml aprotinin, 1 mM DTT) and transferred to a 1.5 ml Eppendorf tube. Cells were pelleted by gentle centrifugation and resuspended in 1 ml of buffer B (buffer A containing 0.2% NP-40). After gentle centrifugation (2000 r.p.m., 20 s) the supernatant (cytosolic extract) was transferred to a fresh tube and the pellet containing the nuclei was resuspended in sucrose solution (buffer A containing 0.25 M sucrose). The nuclei were harvested by centrifugation (2000 r.p.m., 20 s) and lysed in buffer C (50 mM Hepes pH 7.9, 400 mM KCl, 0.1 mM EDTA, 10% glycerol, 1 mM DTT, 0.5 mM PMSF, 10 g/ml leupeptin, 5 g/ml aprotinin,1 mM sodium orthovanadate, 10 mM NaF). The nuclear extract was cleared by centrifugation at 14 000 r.p.m. for 20 min at 4°C.
In vitro MAP-kinase assay
Anti-ERK2 immunoprecipitates (anti-ERK2 agarose beads; Santa Cruz Biotechnology) were washed three times with immunoprecipitation washing buffer containing 1 mM DTT and protease inhibitors and then once in kinase buffer (1 mM DTT, 40 mM MOPS, pH 7.0, 10 mM MgCl 2 ). The precipitates were then resuspended in 30 l of kinase buffer containing 40 mM ATP 10 Ci/l 32 P ␥ATP (Amersham) and 30 g myelin basic protein (MBP; Upstate Biotechnology, Lake Placid, NY, USA). Reactions were incubated at 30°C for 30 min, stopped with SDS sample buffer, and applied to 12% SDS-PAGE
Erythroid differentiation
Hemoglobin producing cells were scored with the benzidine staining method. 9 Briefly, K562 cells were seeded at 5 
Results
HePTP antisense cDNA specifically reduces HePTP protein levels in K562 cells
In K562 cells PMA treatment results in prolonged ERK activation and megakaryocytic differentiation. 6, 7 HePTP is constitutively expressed in K562 cells and overexpression of this PTP interferes with ERK2 activation. 13 To better understand the role of HePTP in ERK regulation and cell differentiation we had previously used a catalytically inactive mutant of HePTP (HePTP-C/S), in which the conserved cystein residue of the PTP active site was replaced with serine, to interfere with the function of endogenous HePTP. In contrast to wild-type HePTP, overexpression of this mutant in K562 cells had no significant effect on PMA-induced tyrosine phosphorylation of ERK1/2. 13 In in vitro kinase assays, however, ERK activity was reduced to similar levels as seen in cells overexpressing wildtype HePTP. 13 In contrast to wild-type HePTP, HePTP-C/S forms a very stable complex with activated and phosphorylated ERK2. This is most likely the result of the combined effects of the KIM motif binding to ERK2 and the inactive HePTP catalytic domain, which binds the ERK phosphoepitopes. 13 The reduced kinase activity of ERK2 in cells expressing HePTP-C/S is likely the result of this complex formation. Consistent with these observations, we did not observe a significant difference between K562 cells overexpressing wildtype HePTP or HePTP-C/S in their ability to differentiate in preliminary experiments (data not shown; see also below). Therefore, we employed an antisense approach to interfere with the expression and activity of endogenous HePTP and to study the effect of reduced HePTP levels on PMA-induced megakaryocytic differentiation of K562 cells.
The complete open reading frame of HePTP was subcloned into a pCDNA expression vector in antisense orientation. After transfection into K562 cells, single cell clones were established and analyzed for HePTP protein levels by immunoblot ( Figure 1a ). Compared to control cells, which had been transfected with the empty vector, several of the antisense clones showed a marked reduction in HePTP protein levels. The HePTP antisense clones No. 3 and No. 8 (HePTP-AS-3/8) were chosen for further analysis. To make sure that the effect seen is specific for HePTP we also analyzed the expression of two related PTPs, TcellPTP and PTP1B. As shown in Figure 1a , no change in the expression of these two PTPs was observed. As an additional control we also used a K562 cell line which overexpresses myc-tagged wild-type HePTP ('sense' in Figure  1a ). While the levels of PTP1B and TcellPTP are not changed as compared to the vector control, an increased level of endogenous HePTP is detectable in this cell line. Similar results were obtained with an independently isolated clone. At this time we do not know if this result is due to upregulation of endogenous HePTP, an increased half-life of the cellular protein, or proteolytic cleavage of the myc-tag from ectopically expressed HePTP. Since HePTP is a negative regulator of ERK we then asked whether downregulation of HePTP would lead to increased basal or PMA-stimulated ERK activity. Vector transfected control cells, cells overexpressing wild-type Leukemia HePTP, and cells expressing HePTP antisense were starved overnight and then stimulated with PMA. After cell lysis and immunoprecipitation with anti-ERK2 antibodies, ERK kinase activity was then determined by in vitro kinase assays using myelin basic protein (MBP) as substrate ( Figure 1b) . As reported previously, overexpression of wild-type HePTP resulted in a marked reduction of PMA-stimulated ERK activation, as compared to control cells. Surprisingly, in repeated experiments, downregulation of HePTP by expression of antisense cDNA had only a marginal effect on basal ERK activity. In addition, the levels of ERK activity observed after PMA stimulation were comparable to the ones seen in control cells. The results demonstrate that downregulation of HePTP does not result in a significant increase in basal or PMA-stimulated ERK activity in K562 cells.
We then performed a more extensive timecourse experiment to test the effect of HePTP on events downstream of ERK activation. Vector transfected control cells, cells overexpressing wild-type HePTP, and HePTP antisense expressing cells were starved and then stimulated with PMA for various times (Figure 2a ). Under the conditions used, no significant ERK phosphorylation was detectable in unstimulated cells. In vector transfected control cells, PMA stimulation resulted in a rapid increase in ERK phosphorylation, as determined by immunoblot with a phospho-specific antibody. As expected, in cells overexpressing wild-type HePTP the overall level of ERK phosphorylation is significantly reduced compared to control cells. Consistent with the in vitro kinase assay (see Figure 1b) , overall PMA-induced ERK phosphorylation was not significantly increased in HePTP-AS cells, as compared to the basal and PMA-induced levels seen in the K562 control, although we observed a slightly faster downregulation of ERK phosphorylation in HePTP-AS cells at the late timepoints (Figure 2a ). This result was consistent between multiple experiments and two independently obtained HePTP antisense clones. In K562 cells, cell cycle arrest and megakaryocytic differentiation are associated with an increase in the protein levels of cyclin D1, as well as of the cyclin-dependent kinase inhibitors p21 and p27. 23 As for the cell cycle arrest, upregulation of these proteins is dependent on the MEK-ERK pathway. 23 As shown in Figure 2b , the cyclin D1 protein levels are upregulated in our panel of K562 cell lines after PMA treatment and the level of cyclin D1 expression as well as the timecourse of induction were independent of HePTP protein levels. To test if HePTP influenced the phosphorylation of cytosolic ERK substrates, we performed immunoblots with anti-paxillin antibodies (Figure 2c ). Recently Ku and Meier 24 demonstrated that PMA-induced phosphorylation of the docking protein paxillin on multiple serine and threonine residues depends on MEK/ERK activation. Here we analyzed the PMAinduced mobility shift of paxillin as an indirect measure of its phosphorylation (Figure 2c ). Similar to the observation of Ku and Meier 24 in EL4 thymoma cells, PMA treatment of K562 cells results in a rapid decrease in the apparent mobility of paxillin on SDS-PAGE. Between 30 and 60 min of stimulation this shift is maximal and after 6 h of PMA stimulation a large fraction of paxillin has returned to its original mobility. Throughout the timecourse examined no significant difference was observed in K562-HePTP-AS8 cells. In cells overexpressing wild-type HePTP, however, the PMA-induced mobility shift was significantly reduced. In summary, neither overexpression nor downregulation of HePTP influences cyclin D1 induction, while overexpression of HePTP, but not inhibition of HePTP, leads to changes in PMA-induced paxillin phosphorylation. 
Inhibition of HePTP enhances nuclear translocation of ERK
As outlined above, we did not observe significant changes in basal or PMA-induced ERK activity in K562-HePTP-AS cells. An important aspect of ERK regulation is nuclear translocation of activated ERK, which is required for the modulation of transcription factors and gene expression. 4 ,5 Therefore we asked whether downregulation of HePTP could lead to enhanced nuclear translocation of ERK in PMA-treated K562 cells. Control cells, cells overexpressing wild-type HePTP and HePTP-AS cells were starved overnight and then stimulated with PMA for 1 and 3 h. In previous experiments we observed maximum ERK phosphorylation in K562 control cells at 1 h of PMA treatment. Cells were harvested and fractionated as described in Materials and methods to obtain cytosolic and nuclear extracts. As shown in Figure 3 (top panel) endogenous HePTP (control in Figure 3a) as well as ectopically expressed HePTP (HePTP-WT in Figure 3a ) are exclusively found in the cytosolic fractions, as expected. No HePTP protein was detected in samples from HePTP-AS8 cells. Immunoblot with antibodies against the cytosolic phosphatase SHP-2 confirmed proper separation of cytosolic and nuclear fractions ( Figure  3a, bottom panel) . In unstimulated control cells the bulk of ERK2 protein is found in the cytosol and a minor fraction is present in the nuclear extract (Figure 3a, 2nd panel) . Both cytosolic and nuclear ERK2 from unstimulated cells could not be detected with a phospho-specific anti-ERK antibody ( Figure  3a, 3rd panel) . After PMA stimulation phosphorylated ERK2 is present in the nuclear fraction of control cells. This is also confirmed by the apparent band shift of ERK2 as seen in the anti-ERK2 immunoblot (Figure 3a, 2nd panel) . Although the overall phosphorylation of ERK2 in HePTP-WT expressing cells is reduced as compared to the control, similar levels of activated ERK2 are present in the nuclear fractions after PMA stimulation. In PMA-treated HePTP-AS8 cells the nuclear translocation of total ERK2 as well as of phosphorylated ERK2 is significantly enhanced, as compared to control cells ( Figure  3a , panels 2 and 3). Also in the absence of PMA stimulation the levels of nuclear ERK2 are increased over the control. As for the other two cell lines, this fraction of ERK2 is not detected by phospho-specific anti-ERK antibodies, suggesting that it is in its inactive form. The results demonstrate that downregulation of HePTP leads to enhanced nuclear translocation of ERK2 in K562 cells.
HePTP contains two consensus ERK phosphorylation sites (T45 and S72) adjacent to the KIM motif and Saxena et al 11 recently suggested that phosphorylation of these sites might interfere with the binding of HePTP to its substrates. Therefore we asked if such a mechanism could explain our observation that ectopic expression of wild-type HePTP has no significant effect on the nuclear translocation of ERK2 in PMA-treated K562 cells (see Figure 3a) . When transiently overexpressed in Jurkat or 293 cells, HePTP is associated with ERK even in the absence of stimulation. 11, 12 In our stable K562 cell lines, however, we have not observed constitutive association of HePTP with ERK2, which might be explained by lower expression levels as compared to transient transfections. To further investigate the association of HePTP with ERK2 we therefore used transient transfection of 293 cells (Figure 3b ). 293 Cells were transfected with empty vector (control) or expression plasmids for MYC-taged wild-type HePTP or the inactive mutant HePTP-C/S. After overnight starvation cells were stimulated with epidermal growth factor (EGF) to activate ERK1/2. The association of HePTP with ERK2 was then analyzed by anti-MYC immunoprecipitation followed by anti-ERK2 immunoblot (Figure 3b, top panel) . Similar to Jurkat cells, we found coprecipitation of ERK2 with wild-type HePTP and with HePTP-C/S in the absence of ERK activation. As shown in the bottom panel of Figure 3a , EGF treatment results in a rapid and transient activation of ERK1 and ERK2 in 293 cells. As expected, the levels of phosphorylated ERK1/2 are reduced in cells transfected with wild-type HePTP relative to control cells. Interestingly, coprecipitation of ERK2 with wild-type HePTP was significantly reduced after ERK2 activation. At later timepoints, when ERK activity starts to decrease, we repeatedly observed an increase in ERK2-HePTP complex formation. In contrast to wild-type HePTP, the substrate trapping mutant HePTP-C/S forms a stable complex with ERK2 and after ERK activation the amount of ERK2 coprecipitating with HePTP-C/S increases, rather than decreases. This is consistent with our previous findings in K562 cells, where HePTP-C/S forms a stable complex with activated and phosphorylated ERK2. These results demonstrate that the association of HePTP with ERK2 is regulated by ERK activity. HePTP associates with inactive ERK2 and is then displaced after ERK activation, possibly as a result of phosphorylation of the ERK consensus sites within the N-terminus of the phosphatase.
Effect of HePTP on PMA-induced cell cycle arrest in K562 cells
Our results with the HePTP antisense expressing cell lines extend previous findings and establish a physiological function for HePTP as a negative regulator of ERK1/2 activity. We then wanted to know if and how HePTP influences megakaryocytic differentiation of K562 cells.
One of the earliest events detectable during PMA-induced megakaryocytic differentiation is growth inhibition and cell cycle arrest. Herrera et al 25 have recently demonstrated that PMA-induced cell cycle arrest of K562 cells is characterized by a significant reduction of cells in the S phase of the cell cycle within 24 h of PMA stimulation. They also demonstrated that this event is dependent on the MEK-ERK pathway. To determine if this cell cycle arrest could be modulated by HePTP we compared the cell cycle profiles of K562 control cells, K562-HePTP-WT cells, and K562-HePTP-AS8 cells after 24 h of PMA treatment (Figure 4 ). When cultured in the absence of PMA, a significant fraction of cells are within S phase (Figure 4, top row) . After 24 h of PMA treatment the S Leukemia phase population of all three cell lines is reduced to similar levels, with a concomitant increase in the G1 and G2/M peaks. Together with the data shown in Figure 2 the results demonstrate that HePTP has no significant effect on PMAinduced cell cycle arrest of K562 cells.
Downregulation of HePTP enhances the expression of megakaryocytic markers in K562 cells
Megakaryocytic differentiation is characterized by growth arrest, cell adhesion, and, finally, a change in cell morphology. The increased adhesive properties of the cells are likely due to an upregulation of integrins and cell surface expression of the integrin gp IIb/IIIa (CD41, CD61) is frequently used as a marker for megakaryocytic differentiation. 26 We had observed that K562 cells expressing HePTP antisense cDNA do attach to the culture dish to a certain degree, while the vector transfected control cells grow only in suspension. Therefore we asked if the megakaryocytic marker CD41 is upregulated in these cells. K562 control cells, K562-HePTP-WT cells, and K562-HePTP-AS cells were cultured with or without PMA for 48 h, and then analyzed for cell surface expression of CD41 by flow cytometry. As shown in Figure  5a , PMA treatment resulted in a significant upregulation of CD41 in K562 control cells (Figure 5a, top panel) . In cells overexpressing wild-type HePTP this effect was markedly reduced (Figure 5a, middle panel) . In cells expressing HePTP antisense cDNA, we could not observe an increase in the basal level of CD41 expression, as compared to the control. The PMA treated cells, however, expressed CD41 to much higher levels than the PMA-treated control cells.
The cytokine IL-6 can also induce CD41 upregulation and megakaryocytic differentiation.
27,28 Therefore we tested if downregulation of HePTP also leads to enhanced CD41 expression in response to IL-6. As shown in Figure 5b , we obtained similar results when we treated the cells with IL-6 instead of PMA, although the difference between control and antisense expressing cells was somewhat less pronounced. In K562 cells CD41 upregulation is dependent on sustained ERK activation. 7 To confirm that the lower CD41 level observed in K562-HePTP-WT cells is a consequence of reduced ERK activity, due to HePTP overexpression, we asked whether this effect could be reversed by increasing cellular ERK2 levels. K562 control cells and K562-HePTP-WT cells were transfected with an expression plasmid for wild-type ERK2 and then processed for the analysis of PMA-induced CD41 expression as described above. As shown in Figure 5c , transfection of K562 control cells and K562-HePTP-WT cells with ERK2 resulted in increased CD41 levels after PMA stimulation, as compared to a mock-transfected control. The basal level of CD41 expression was not affected by ERK2 transfection. Immunoblot analysis with anti-ERK2 antibodies confirmed expression of the ERK2 transgene (not shown). Together these results demonstrate that HePTP, through regulation of ERK activity, can modulate CD41 expression in K562 cells.
In addition to CD41 we also tested if production of IL-6, a cytokine that is induced and secreted by K562 cells in response to PMA stimulation, is modulated by the level of HePTP expression. 27 As shown in Figure 6 , PMA-induced production of IL-6 is increased about 2.5 to three-fold over the levels detected in the conditioned media from K562 control cells. In addition, the antisense expressing clones analyzed exhibited a significant increase in the basal levels of IL-6 secretion. Similar to what we have observed for CD41 expression, IL-6 production is impaired in K562-HePTP-WT cells. Together, these data show that HePTP protein levels can modulate the expression of megakaryocytic markers following PMA stimulation. Although K562 cells expressing HePTP antisense cDNA show increased adhesive properties (see Figure  7) , we did not observe an increase in the basal or unstimulated expression of CD41 nor significant changes in paxillin phosphorylation, suggesting that possibly upregulation of other integrins may be responsible for this effect. Effect of HePTP on IL-6 production by K562 cells. The indicated cell lines were left untreated or were treated with 100 nM PMA for 48 h. The content of IL-6 in the media was then determined by ELISA as described in Materials and methods. The data are representative of three independent experiments. type was even less than that for K562-HePTP-WT cells. The results demonstrate that HePTP is required for K562 cells to undergo the complete megakaryocytic differentiation program.
HePTP is required for expression of a fully differentiated megakaryocytic phenotype
Changes in HePTP expression affect erythroid differentiation of K562 cells
The data presented above demonstrate that the downregulation of HePTP affects some but not all aspects of megakaryocytic differentiation. Complete morphological differentiation, however, is impaired. K562 cells are a pluripotent line and these cells can be triggered to undergo megakaryocytic as well as erythroid differentiation. Erythroid differentiation is also associated with changes in MAP-kinase signaling. 8, 9 Therefore we asked whether modulation of HePTP expression would have any effect on the erythroid differentiation of K562 cells. For this purpose, we treated our various K562 cell lines with the kinase inhibitor Herbimycin A which induces erythroid differentiation (Ref. 9 and references therein). Erythroid differentiation was then determined by analyzing cells for hemoglobin expression, using the benzidine staining assay. 9 As shown in Figure 8 , all cell lines showed only a very small percentage (2 to 3%) of hemoglobine positive cells in the absence of Herbimycin A treatment. In the presence of Herbimycin A 40% of K562 control cells were positive for hemoglobine after 4 days. Cells expressing wild-type HePTP or HePTP antisense also showed erythroid differentiation, however, with lower frequency. For these two lines only 20% of cells stained positive for hemoglobin. Compared to control K562 cells, cells expressing HePTP-C/S were most strongly affected their potential to undergo erythroid differentiation. This line showed only 10% differentiation in the presence of Herbimycin A. These results show that, similar to megakaryocytic differentiation, both overexpression as well as inhibition of HePTP interferes with erythroid differentiation.
Discussion
In various cell systems, it has been demonstrated that the magnitude and duration of ERK activation are important factors that determine the response to a particular stimulus. These parameters are to a large degree dependent on the type or combination of stimuli as well as the expression and activity of MKPs. The family of MKPs has recently been extended to include the PTPs, STEP, PTP-SL and HePTP (reviewed in Ref. 10) . Little is known, however, about the involvement of MKPs in the regulation of ERK-mediated responses, such as cell proliferation, differentiation, or apoptosis.
In the present report, we have investigated the function of HePTP in the regulation of ERK-dependent cellular responses, using megakaryocytic differentiation of K562 cells as a model system. While HePTP interacts with ERK1/2 as well as p38 to similar degrees in T cells, ERK2 is the preferred HePTP substrate in K562 cells.
11,13 ERK2, but not p38 gets activated in K562 cells in response to PMA. 13 HePTP is constitutively expressed in K562 cells and overexpression of this PTP interferes with ERK2 activation. 13 To better understand the role of HePTP in ERK regulation and cell differentiation, we established stable K562 cell lines in which the expression of endogenous HePTP is inhibited by HePTP antisense cDNA. The results demonstrate that HePTP regulates nuclear translocation of ERK, and that downregulation of HePTP affects some but not all ERK-dependent aspects of K562 cell megakaryocytic differentiation.
An important question was how downregulation of HePTP influences the magnitude and duration of PMA-induced ERK phosphorylation in K562 cells. Saxena et al 21 demonstrated in Jurkat cells that blocking the interaction of HePTP with ERK1/2 by phosphorylating the PKA consensus site within the KIM of HePTP resulted in significant ERK1/2 activation. In contrast to this, we did not observe significantly increased ERK2 activity in K562 cells in which HePTP levels are downregulated as a result of antisense expression (Figures 2a and 3a) . This was consistent between multiple experiments and different HePTP antisense cDNA expressing clones analyzed. In addition, when cells were grown in complete media containing 10% FBS the levels of ERK1/2 phosphorylation were comparable between HePTP antisense expressing cells and K562 control cells (data not shown). The somewhat faster downregulation of ERK phosphorylation observed after prolonged exposure of K562-HePTP-AS cells to PMA (6 h; see Figure 2a ) could be the result of inactivation by other MKPs. Therefore we asked if other MKPs were upregulated in K562 cells expressing HePTP antisense cDNA. With the antibodies available to us, however, we were unable to detect expression of MKP-3 or PAC-1 in K562 cells (data not shown). MKP-2 was constitutively expressed in all cell lines and the protein levels were not affected by HePTP. We did detect low expression of MKP-1 and the levels in HePTP antisense expressing cells were slightly higher than in control cells, although this was not a consistent result (data not shown). At the present time we do not know if this is of significance, as other MKP family members, such as VHR and MKP-4, as well as serine/threonine phosphatases, such as PP2A, may be involved in the regulation of ERK activity in K562 cells (see also Ref. 10 for review).
Although downregulation of HePTP by antisense cDNA did not result in increased ERK activity, we did observe a significant increase in the nuclear levels of ERK2 in both unstimulated and PMA-stimulated K562-HePTP-AS cells, suggesting that the loss of HePTP facilitates nuclear translocation of ERK2. Interestingly, we did observe a significant increase of unphosphorylated ERK2 in the nuclear fraction of K562-HePTP-AS cells. This result could indicate that one function of HePTP might be to retain ERK2 in the cytosol before ERK activation (see Figure 3a ). Upon activation, ERK then gets released from the complex and translocates to the nucleus. Our coprecipitation experiment is in support of such a model. It appears that the affinity of wild-type HePTP for inactive ERK2 is relatively low, since we have not observed coprecipitation in K562 cells. In systems that allow transient overexpression, however, there is clear binding of wild-type HePTP to inactive ERK2 (Figure 3b) . 11, 12 Upon ERK activation this complex is disrupted, which is demonstrated by reduced coprecipitation of ERK2 with HePTP (Figure 3b ). Over time, as ERK activity decreases after stimulation, we then observed re-formation of the ERK2-HePTP complex. These findings are important, as they explain why overexpression of HePTP has no significant effect on the nuclear translocation of activated ERK2. It is very likely that the regulation of ERK-HePTP binding is regulated through phosphorylation of HePTP by activated ERK, as already suggested in the literature. 11 Our results further support this model and implicate HePTP in the retention of inactive ERK in the cytosol.
To explain the requirement for prolonged ERK1/2 activity for megakaryocytic differentiation, Racke et al 7 proposed a Leukemia two-step model which involves the production of an autocrine factor, which then is ultimately required for the induction of differentiation. This model is supported by the observations that there is a 24-h delay between TPA stimulation and CD41 induction and that K562 cell differentiation can be induced by conditioned media. 7 One good candidate for such an autocrine factor is the cytokine IL-6. IL-6 is produced by K562 cells after PMA stimulation and is able to induce megakaryocytic differentiation in vitro and in vivo (Refs 27, 28 and references therein). As mentioned above, antisense inhibition of HePTP results in increased cell surface expression of CD41 as well as increased secretion of IL-6. HePTP overexpression, on the other hand, reduces both IL-6 secretion and CD41 expression. This may suggest a requirement of HePTP in the regulation of IL-6 expression, and that the enhanced induction of CD41 by K562-HePTP-AS cells might be a direct consequence of elevated IL-6 production.
Several lines of evidence suggest that the effect of HePTP on the expression of CD41 is directly related to the modulation of ERK activity and may not involve other MAP-kinases such as p38 or JNK. First, we have previously demonstrated that ERK is the preferred HePTP substrate in K562 cells. 13 Second, under the conditions used, we have not observed detectable activation of p38 or JNK in K562 cells in response to PMA stimulation, indicating that these two kinases do not play a significant role in this system. In K562 cells we found p38 only activated in response to cellular stress, such as osmotic shock with sorbitol (Ref. 13 and data not shown). Third, ectopic expression of ERK2 could rescue the inhibitory effect of HePTP overexpression on PMA-iduced CD41 expression (Figure 5c ). These results further emphasize the requirement for ERK during K562 cell differentiation.
While the expression of megakaryocytic markers was increased in K562 cells expressing HePTP antisense cDNA ( Figures 5 and 6 ), the development of a fully differentiated phenotype was significantly impaired (Figure 7 ). Megakaryocytic differentiation of K562 cells requires sustained activation of the MEK-ERK pathway. 6, 7 Racke et al 7 have also demonstrated that inhibition of the ERK-activating kinase MEK with the PD098059 compound up to 18 h after PMA stimulation was still effective in blocking CD41 upregulation. In the HePTP antisense cDNA-expressing cells, PMA-induced upregulation of CD41 as well as IL-6 production is significantly increased. Further, PMA-induced cell cycle arrest and induction of cyclin D1 is not changed by overexpression or by inhibition of HePTP. Consequently, HePTP must be required for a relatively late step during differentiation. We do not yet know which aspect(s) of differentiation is affected in K562 cells lacking HePTP. One possibility is a function of HePTP in the regulation of cytoskeletal structures. When completing the megakaryocytic differentiation program K562 cells undergo a dramatic change in cell morphology, which requires the rearrangement of the cytoskeleton. 29 ERK kinases have been demonstrated to interact with several components of the cytoskeleton and may be involved in the regulation of these structures (reviewed in Ref. 2) . Alternatively, the loss of HePTP may result in a defect in integrin signaling.
The results presented further demonstrate that the different steps along the megakaryocytic differentiation pathway differ markedly with regards to their requirement for ERK activity. Surprisingly, the low levels of ERK phosphorylation observed in K562-HePTP-WT cells were sufficient to drive the cells into a cell cycle arrest and for upregulation of cyclin D1. Cell cycle arrest and cyclin D1 induction are dependent on the MEK-ERK pathway in K562 cells. 23, 25 The results further indicate that cell cycle arrest, although a requirement, is not sufficient to initiate megakaryocytic differentiation of K562 cells. Induction of IL-6 and CD41, on the other hand, are severely impaired in these cells. These observations suggest the existence of at least two different threshold levels for ERK activity during different steps of megakaryocytic differentiation. A certain base level of ERK activity is required for the cells to proliferate under uninduced conditions. 9 Cell cycle arrest then requires increased ERK activity over a relatively low threshold level. The upregulation of megakaryocytic markers, however, appears to require even higher levels of ERK activity.
We have also tested the effect of HePTP on erythroid differentiation of K562 cells. Similar to the effect on the establishment of a fully differentiated megakaryocytic phenotype, both overexpression and inhibition of HePTP reduced the percentage of hemoglobin-positive cells after Herbimycin A treatment. Recent reports demonstrate that modulation of ERK and p38 activity is also involved in erythroid differentiation. Shelly et al 8 showed that the inhibition of basal ERK activity promoted erythroid differentiation. Similarly, Uchida et al 30 reported that inhibition of ERK1/2 promoted EPO-induced erythroid differentiation and inhibited TPO-induced megakaryocytic differentiation. Consistent with this, other reports suggest that ERK activation is required for megakaryocytic differentiation and that erythroid differentiation requires p38 activation. 31, 32 Here, it should be noted that we have not observed an effect of HePTP overexpression or HePTP inhibition on the basal activity of ERK in K562 cells (see Figure  1b) . In contrast to the above mentioned reports, Woessman and Mivechi 33 found that a dominant negative ERK1 blocked hemin-induced erythroid differentiation of K562 cells. It was also shown that sodium butyrate, another inducer of erythroid differentiation of K562 cells, transiently induces ERK activity. 34 Collectively, these data may suggest that, similar to other systems of cellular differentiation, the levels and kinetics of ERK activation may be an important factor in determining the fate of K562 cells. Interestingly, Uchida et al 30 also observed that EPO, an inducer of erythroid differentiation, results in rapid and transient ERK activity, while TPO, which induces megakaryocytic differentiation, gave slower but prolonged ERK activation. Together, our data indicate that changes in the regulation of ERK activity, as a result of overexpression or inhibition of HePTP, interferes with erythroid and with megakaryocytic differentiation of K562 cells.
While this manuscript was in preparation, Gronda et al 35 reported on the knockout of HePTP. HePTP −/− mice have no obvious phenotypic defect and all aspects of hematopoiesis, including megakaryocytic development, appear normal. This suggests that other regulatory mechanisms compensate for the loss of HePTP in vivo. Spleen cells isolated from HePTP −/− mice did not show a significant increase of basal ERK phosphorylation, consistent with our results. Upon treatment with PMA or after TCR activation, however, HePTP -/-cells showed enhanced ERK phosphorylation. 35 In HePTP −/− cells this increase in ERK phosphorylation/activity does not manifest itself on the level of cell proliferation or the expression of lineage and activation-specific cell surface markers. 35 In contrast, in our K562 cell system inhibition of HePTP expression has clear phenotypic consequences. This may suggest that in K562 cells some aspects of ERK regulation may be different as compared to primary cells. It may also indicate that in transformed cells significant changes in regulatory components, such as overexpression or deletion of HePTP (see below), may have phenotypic consequences that would otherwise not be obvious. In this context it is interesting to note that PTP1B −/− mouse fibroblasts immortalized with the SV40 Large T antigen show alterations in adhesion and integrin signaling, while PTP1B −/− primary fibroblasts exhibit only very subtle changes in this pathway compared to wild-type cells. 36 In conclusion, we propose that one important function of HePTP is the regulation of ERK1/2 nuclear translocation, rather than regulation of basal ERK activity. Furthermore, it appears that different aspects of K562 cell megakaryocytic differentiation have quite distinct requirements with regard to ERK activity, and that the outcome of ERK2 activation can be modulated by HePTP protein levels. Interestingly, both the loss of the HePTP gene as well as overexpression of HePTP have been linked to hematopoietic malignancies. The HePTP gene is located on chromosome 1q32.1, a region frequently amplified in patients with myelodysplastic syndrome, a preleukemic condition. 16, 37 Amplification and overexpression of the HePTP gene was reported for a patient with myeloid dysplasia. 37 On the other hand, deletions of 1q32 have been detected in lymphoproliferative disorders and non-Hodgkin lymphomas. 38 In K562 cells both overexpression and inhibition of HePTP interferes with terminal differentiation. In this respect, it will be interesting to determine if aberrant levels of HePTP in other leukemic cell types might interfere with differentiation and thus favor cell proliferation.
